Genetically edition of anti-CD19 CAR-T cells to disrupt expression of the endogenous TCR for inhibition of GVHD progress could display the anticipated property of conventional CD19-specific CAR-T cells without responding to TCR stimulation [126]. Here, CD19 is linked to graft versus host disease.